|
1
|
Podratz JL, Lee H, Knorr P, Koehler S,
Forsythe S, Lambrecht K, Arias S, Schmidt K, Steinhoff G, Yudintsev
G, et al: Cisplatin induces mitochondrial deficits in Drosophila
larval segmental nerve. Neurobiol Dis. 97:60–69. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bobylev I, Joshi AR, Barham M, Neiss WF
and Lehmann HC: Depletion of mitofusin-2 causes mitochondrial
damage in cisplatin-induced neuropathy. Mol Neurobiol.
55:1227–1235. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shkalim-Zemer V, Ash S, Toledano H,
Kollender Y, Issakov J, Yaniv I and Cohen IJ: Highly effective
reduced toxicity dose-intensive pilot protocol for non-metastatic
limb osteogenic sarcoma (SCOS 89. Cancer Chemother Pharmacol.
76:909–916. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma G, Cai H, Gao L, Wang M and Wang H:
sCLU regulates cisplatin chemosensitivity of lung cancer cells in
vivo. World J Surg Oncol. 13:802015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li P, Yang X, Cheng Y, Zhang X, Yang C,
Deng X, Li P, Tao J, Yang H, Wei J, et al: MicroRNA-218 increases
the sensitivity of bladder cancer to cisplatin by targeting Glut1.
Cell Physiol Biochem. 41:921–932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Allen JC, Kirschner A, Scarpato KR and
Morgans AK: Current management of refractory germ cell tumors and
future directions. Curr Oncol Rep. 19:82017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pellat A, Wislez M, Svrcek M, Hammel P,
Afchain P and Andre T: Therapeutic management of poorly
differentiated neuroendocrine lung tumors and neuroendocrine
carcinomas of the digestive system. Bull Cancer. 103:880–895. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Durusu IZ, Husnugil HH, Atas H, Biber A,
Gerekci S, Gulec EA and Özen C: Anti-cancer effect of clofazimine
as a single agent and in combination with cisplatin on U266
multiple myeloma cell line. Leuk Res. 55:33–40. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Starkov AK, Zamay TN, Savchenko AA,
Ingevatkin EV, Titova NM, Kolovskaya OS, Luzan NA, Silkin PP and
Kuznetsova SA: Antitumor effect of arabinogalactan and platinum
complex. Dokl Biochem Biophys. 467:92–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jamesdaniel S, Rathinam R and Neumann WL:
Targeting nitrative stress for attenuating cisplatin-induced
downregulation of cochlear LIM domain only 4 and ototoxicity. Redox
Biol. 10:257–265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leo M, Schmitt LI, Erkel M, Melnikova M,
Thomale J and Hagenacker T: Cisplatin-induced neuropathic pain is
mediated by upregulation of N-type voltage-gated calcium channels
in dorsal root ganglion neurons. Exp Neurol. 288:62–74. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee J, Kim HH, Ro SM and Yang JH:
Capecitabine and cisplatin (XP) combination systemic chemotherapy
in heavily pre-treated HER2 negative metastatic breast cancer. PLoS
One. 12:e01716052017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vergaro V, Papadia P, Petrini P, Fanizzi
FP, De Pascali SA, Baldassarre F, Pastorino L and Ciccarella G:
Nanostructured polysaccharidic microcapsules for intracellular
release of cisplatin. Int J Biol Macromol. 99:187–195. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cherniawsky H, Merchant N, Sawyer M and Ho
M: A case report of posterior reversible encephalopathy syndrome in
a patient receiving gemcitabine and cisplatin. Medicine
(Baltimore). 96:e58502017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hassan SM, Khalaf MM, Sadek SA and
Abo-Youssef AM: Protective effects of apigenin and myricetin
against cisplatin-induced nephrotoxicity in mice. Pharm Biol.
55:766–774. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karafakioglu YS, Bozkurt MF, Hazman O and
Fidan AF: Efficacy of safranal to cisplatin-induced nephrotoxicity.
Biochem J. 474:1195–1203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sokolova O and Naumann M: NF-κB signaling
in gastric cancer. Toxins. 9(pii): E1192017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen XZ, Chen H, Castro FA, Hu JK and
Brenner H: Epstein-Barr virus infection and gastric cancer: A
systematic review. Medicine (Baltimore). 94:e7922015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang C, Zhang J, Cai M, Zhu Z, Gu W, Yu Y
and Zhang X: DBGC: A database of human gastric cancer. PLoS One.
10:e01425912015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Long ZW, Yu HM, Wang YN, Liu D, Chen YZ,
Zhao YX and Bai L: Association of IL-17 polymorphisms with gastric
cancer risk in Asian populations. World J Gastroenterol.
21:5707–5718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu HH, Lin WC and Tsai KW: Advances in
molecular biomarkers for gastric cancer: miRNAs as emerging novel
cancer markers. Expert Rev Mol Med. 16:e12014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang D, Duan H, Huang H, Tong X, Han Y,
Ru G, Qu L, Shou C and Zhao Z: Cisplatin resistance in gastric
cancer cells is associated with HER2 upregulation-induced
epithelial-mesenchymal transition. Sci Rep. 6:205022016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X,
Zhang J, Qiang F, Li A, Roe OD, et al: TXNL1-XRCC1 pathway
regulates cisplatin-induced cell death and contributes to
resistance in human gastric cancer. Cell Death Dis. 5:e10552014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Korobkina EA, Knyazeva MS, Kil YV, Titov
SE and Malek AV: Comparative analysis of RT-qPCR based
methodologies for microRNA detection. Klin Lab Diagn. 63:722–728.
2018.PubMed/NCBI
|
|
25
|
Kumar D, Das PK and Sarmah BK: Reference
gene validation for normalization of RT-qPCR assay associated with
germination and survival of rice under hypoxic condition. J Appl
Genet. 59:419–430. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zou J, Dong X, Li Y, Tong S, Wang J, Liao
M and Huang G: Deep sequencing identification of differentially
expressed miRNAs in the spinal cord of resiniferatoxin-treated rats
in response to electroacupuncture. Neurotox Res. May 23–2019.(Epub
ahead of print). View Article : Google Scholar
|
|
27
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The Gene
Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
The Gene Ontology Consortium: The Gene
Ontology Resource: 20 years and still GOing strong. Nucleic Acids
Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kanehisa M, Sato Y, Furumichi M, Morishima
K and Tanabe M: New approach for understanding genome variations in
KEGG. Nucleic Acids Res. 47:D590–D595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife:. 4:e050052015. View Article : Google Scholar :
|
|
31
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res 43 (Database Issue). D146–D152. 2015. View Article : Google Scholar
|
|
32
|
Fock KM: Review article: The epidemiology
and prevention of gastric cancer. Aliment Pharmacol Ther.
40:250–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kamata S, Kishimoto T, Kobayashi S,
Miyazaki M and Ishikura H: Possible involvement of persistent
activity of the mammalian target of rapamycin pathway in the
cisplatin resistance of AFP-producing gastric cancer cells. Cancer
Biol Ther. 6:1036–1043. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He J, Qi H, Chen F and Cao C: MicroRNA-25
contributes to cisplatin resistance in gastric cancer cells by
inhibiting forkhead box O3a. Oncol Lett. 14:6097–6102.
2017.PubMed/NCBI
|
|
35
|
Li X, Liang J, Liu YX, Wang Y, Yang XH,
Luan BH, Zhang GL, Du J and Wu XH: miR-149 reverses cisplatin
resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Die Pharmazie. 71:640–643. 2016.PubMed/NCBI
|
|
36
|
Silberman H: Perioperative adjunctive
treatment in the management of operable gastric cancer. J Surg
Oncol. 90:174–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ajani JA, Buyse M, Lichinitser M,
Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha
R, Carrato A, et al: Combination of cisplatin/S-1 in the treatment
of patients with advanced gastric or gastroesophageal
adenocarcinoma: Results of noninferiority and safety analyses
compared with cisplatin/5-fluorouracil in the First-Line Advanced
Gastric Cancer Study. Eur J Cancer. 49:3616–3624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park SC and Chun HJ: Chemotherapy for
advanced gastric cancer: Review and update of current practices.
Gut Liver. 7:385–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xia S, Guo J, Li J, Zhou L and Zhao Y:
Application of miRNAs in the occurrence and early diagnosis of
pancreatic cancer. Zhonghua Wai Ke Za Zhi. 52:198–201. 2014.(In
Chinese). PubMed/NCBI
|
|
41
|
Wang CM, Yang XL, Liu MH, Cheng BH, Chen J
and Bai B: High-throughput sequencing analysis of differentially
expressed miRNAs and target genes in ischemia/reperfusion injury
and apelin-13 neuroprotection. Neural Regen Res. 13:265–271. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun X, Huang T, Liu Z, Sun M and Luo S:
LncRNA SNHG7 contributes to tumorigenesis and progression in breast
cancer by interacting with miR-34a through EMT initiation and the
Notch-1 pathway. Eur J Pharmacol. 856:1724072019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu M, Zheng Z, Huang J, Ma X, Huang C, Wu
R, Li X, Liang Z, Deng F, Wu J, et al: Modulation of miR-34a in
curcumin-induced antiproliferation of prostate cancer cells. J Cell
Biochem. May 1–2019.(Epub ahead of print).
|
|
44
|
Fukuda K, Arigami T, Yanagita S,
Matsushita D, Okubo K, Kijima T, Uenosono Y, Ishigami S and
Natsugoe S: A case of advanced gastric cancer showing pathological
complete response after neoadjuvant chemotherapy with S-1 and
oxaliplatin. Gan To Kagaku Ryoho. 46:471–473. 2019.PubMed/NCBI
|
|
45
|
Kalapanida D, Zagouri F, Gazouli M,
Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis
TN, Kastritis E, Terpos E, et al: Evaluation of pre-mir-34a
rs72631823 single nucleotide polymorphism in triple negative breast
cancer: A case-control study. Oncotarget. 9:36906–36913. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Orosz E, Kiss I, Gyongyi Z and Varjas T:
Expression of circulating miR-155, miR-21, miR-221, miR-30a,
miR-34a and miR-29a: Comparison of colonic and rectal cancer. In
Vivo. 32:1333–1337. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Anauate AC, Leal MF, Wisnieski F, Santos
LC, Gigek CO, Chen ES, Calcagno DQ, Assumpcao PP, Demachki S,
Arasaki CH, et al: Analysis of 8q24.21 miRNA cluster expression and
copy number variation in gastric cancer. Future Med Chem. May
29–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Z, Dong Y, Hua J, Xue H, Hu J, Jiang
T, Shi L and Du J: A five-miRNA signature predicts survival in
gastric cancer using bioinformatics analysis. Gene. 699:125–134.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hibino S, Saito Y, Muramatsu T, Otani A,
Kasai Y, Kimura M and Saito H: Inhibitors of enhancer of zeste
homolog 2 (EZH2) activate tumor-suppressor microRNAs in human
cancer cells. Oncogenesis. 3:e1042014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim G, An HJ, Lee MJ, Song JY, Jeong JY,
Lee JH and Jeong HC: Hsa-miR-1246 and hsa-miR-1290 are associated
with stemness and invasiveness of non-small cell lung cancer. Lung
Cancer. 91:15–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
